Seres Therapeutics (MCRB) Leases (2019 - 2025)
Historic Leases for Seres Therapeutics (MCRB) over the last 7 years, with Q3 2025 value amounting to $74.7 million.
- Seres Therapeutics' Leases fell 993.97% to $74.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.7 million, marking a year-over-year decrease of 993.97%. This contributed to the annual value of $80.9 million for FY2024, which is 1052.24% down from last year.
- Per Seres Therapeutics' latest filing, its Leases stood at $74.7 million for Q3 2025, which was down 993.97% from $76.8 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Leases ranged from a high of $111.0 million in Q4 2022 and a low of $8.4 million during Q1 2021
- Moreover, its 5-year median value for Leases was $78.9 million (2025), whereas its average is $66.2 million.
- Its Leases has fluctuated over the past 5 years, first soared by 50953.43% in 2022, then tumbled by 2564.63% in 2025.
- Quarter analysis of 5 years shows Seres Therapeutics' Leases stood at $18.2 million in 2021, then soared by 509.53% to $111.0 million in 2022, then dropped by 18.53% to $90.4 million in 2023, then decreased by 10.52% to $80.9 million in 2024, then fell by 7.71% to $74.7 million in 2025.
- Its last three reported values are $74.7 million in Q3 2025, $76.8 million for Q2 2025, and $78.9 million during Q1 2025.